Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
about
Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbiditiesOATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryExpression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral DrugsNovel mechanism of impaired function of organic anion-transporting polypeptide 1B3 in human hepatocytes: post-translational regulation of OATP1B3 by protein kinase C activation.Pharmacogenomics of antimicrobial agents.Heterogeneous accumulation of fluorescent bile acids in primary rat hepatocytes does not correlate with their homogenous expression of ntcp.Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapyPotent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease InhibitorsPharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai AdultsEffect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIsExternal validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Transporter-mediated drug-drug interactions.Drug-permeability and transporter assays in Caco-2 and MDCK cell lines.Role of transporters in drug interactions.The role of physiologically based pharmacokinetic modeling in regulatory review.Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroRole of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters.Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells.Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach.Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
P2860
Q26853274-AF24375C-9E95-4DBD-B92F-5257A07BC54DQ27001267-C939E438-2ECA-4FDE-8782-4B1678CDC29BQ28081272-46651AD6-8154-4F8F-A2D0-1C52AE5C09C0Q28548592-C8C40269-0F56-4D8F-8AFE-EDC0AB5E7208Q34360004-DC02F169-2230-409B-B589-086810074951Q34977413-3C4FE30E-0B14-45CC-B7F0-AB3381CB693AQ35087112-64CC31CA-E136-4243-9DAB-0B1A85BBADF7Q35501523-26D04B10-D3A9-4F3C-9920-476BB262F0FBQ35595787-36A4471A-C8AC-4262-A992-938391E301FEQ36186145-7ED5BA17-8093-4671-AEFD-D97900354F8BQ36359372-3D849B44-2D40-40AF-A471-161B8CE3D363Q36439164-7155E225-FDC9-4BDE-8200-033B84455259Q36599597-702D57F8-EEA3-486A-8D21-9B72DC154B41Q36693701-FD411293-23AF-4743-92FF-C2BB4D1B5C95Q36746173-25E2246D-F1A1-48F4-B111-CEA3F0771197Q36763108-08DDB658-C86E-4EED-AD66-D8F248991FD4Q36835199-270D36B8-6B61-4115-A54A-6B986905A92BQ37113947-F439AABA-8296-4BEF-A04B-15A59A515DCBQ37251993-0CE1DD07-9B97-429F-9485-B278391EF02EQ37631771-14BD2645-A11D-46C8-B362-AB0C849603A2Q37855801-901CF062-336E-4E2D-B4A6-1FD51D42E605Q37905033-184BDD10-4A76-4FBB-B99A-B4CF93BACC71Q37958069-042C209B-3E77-4CF3-A578-69516463427DQ37964577-97AEC28B-E3CB-414F-8DBC-0F7DB5EA07BDQ37982653-A7196F09-BE1D-4508-8351-AC6150A73F67Q38051447-61625150-DEA1-4374-BFAD-0517FA4F0504Q38071700-A3798EF8-69B0-446C-8689-E01DEE7A8B81Q38222092-AE40E489-C9E9-4B3B-9F12-D61F75CF9C92Q38324557-C1874723-1292-4C4A-A712-229AD4A9AFC0Q38478413-478266ED-9D38-42E8-9EB8-42E3EBB847D0Q38714220-129F75A7-CF10-4F47-8401-55BD07C32CB8Q38963389-4424315E-8352-4C82-AC14-05436DBD9FF4Q39229674-41BAFB6E-6F98-45FB-A08C-0F55024DD2FEQ39552173-19B3703E-0DAC-45B5-B048-4FA7CC463F48Q40162850-0029EEBF-191E-459C-9258-4998FD123224Q40180951-8FBF0A2C-3E8F-46B6-9DE1-B66DEE19497EQ40488073-ED9D372E-BB9C-4773-B71D-BA5A95785164Q40717885-E22EEDB7-0CFD-433E-910F-EDB120842DBDQ40916355-1190463E-FB35-4769-82BA-6652A73602C1Q41015337-84820CAB-5432-4535-896D-472CFBD35816
P2860
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@ast
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@en
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@nl
type
label
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@ast
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@en
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@nl
prefLabel
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@ast
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@en
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
@nl
P2093
P2860
P1433
P1476
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1
@en
P2093
P2860
P304
P356
10.3109/00498250903509375
P407
P577
2010-03-01T00:00:00Z